Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic

Pediatrics

Volumn 135, Issue 6, 2015, Pages 981-989

  Acosta, Anna M ^a,b   DeBolt, Chas ^c   Tasslimi, Azadeh ^c   Lewis, Melissa ^a   Stewart, Laurie K ^c   Misegades, Lara K ^b   Messonnier, Nancy E ^b   Clark, Thomas A ^b   Martin, Stacey W ^b   Patel, Manisha ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; EPIDEMIC; ETHNICITY; FEMALE; GROUPS BY AGE; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PERTUSSIS; PRIORITY JOURNAL; TREATMENT DURATION; UNITED STATES; VACCINATION; CASE CONTROL STUDY; CHILD; EVALUATION STUDY; WHOOPING COUGH;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; WASHINGTON; WHOOPING COUGH;

EID: 84930586722     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-3358     Document Type: Article

References (35)

1. Division of Integrated Surveillance Systems and Services, National Center for Public Health Informatics, Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention, US Department of Health and Human Services. National Notifiable Disease Surveillance System. Available at: www.cdc.gov/pertussis/surv-reporting.html. Accessed August 12, 2013
2. Centers for Disease Control and Prevention. Pertussis epidemic - Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012;61(28):517-522
3. Winter K, Harriman K, Zipprich J, et al. California pertussis epidemic, 2010. J Pediatr. 2012;161(6):1091-1096
4. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308(20):2126-2132
5. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012-1019
6. Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131(4):e1047-e1052
7. Baxter R, Bartlett J, Rowhani-Rahbar A, Fireman B, Klein NP. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ. 2013;347:f4249
8. Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J. 2009;28(2):152-153
9. Skoff TH, Martin K, Cohn A, et al. Tdap vaccine effectiveness among adolescents: a case-control study in Minnesota. Talk presented at: 9th International Bordetella Symposium; September 30, 2010; Baltimore, MD.
10. Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis. 2010;51(3):315-321
11. Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis. 2014;210(6):942-953
12. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years - United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(34):685-693
13. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep. 1997;46(RR-10):25
14. Washington State Department of Health. Pertussis: reporting and surveillance guidelines. Available at: www.doh.wa.gov/Portals/1/Documents/5100/420-066-Guideline-Pertussis.pdf#nameddest=casedef. Accessed August 12, 2013
15. Washington State Department of Health. About the Washington State Immunization Information System. Available at: www.doh.wa.gov/ForPublicHealthandHealthcareProviders/HealthcareProfessionsandFacilities/DataReportingandRetrieval/ImmunizationInformationSystem/Aboutus.aspx. Accessed February 14, 2014
16. Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-7):1-25
17. Guyer B, Smith DR, Chalk R. Calling the shots: immunization finance policies and practices. Executive summary of the report of the Institute of Medicine. Am J Prev Med. 2000;19(3 suppl):4-12
18. Howell-White SR, Rosato NS. Examination of universal vaccine purchasing states and New Jersey. New Brunswick, NJ: Rutgers Center for State Health Policy; 2005
19. Broder KR, Cortese MM, Iskander JK, et al Advisory Committee on Immunization Practices. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1-34
20. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61(34):671-677
21. Ward JI, Cherry JD, Chang SJ, et al APERT Study Group. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555-1563
22. Skoff TH, Cohn AC, Clark TA, Messonnier NE, Martin SW. Early impact of the US Tdap vaccination program on pertussis trends. Arch Pediatr Adolesc Med. 2012;166(4):344-349
23. Hendrikx LH, Berbers GA, Veenhoven RH, Sanders EA, Buisman AM. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine. 2009;27(47):6530-6536
24. Vermeulen F, Dirix V, Verscheure V, et al. Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. Vaccine. 2013;31(15):1981-1986
25. Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun. 1997;65(6):2168-2174
26. Leef M, Elkins KL, Barbic J, Shahin RD. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med. 2000;191(11):1841-1852
27. Rieber N, Graf A, Hartl D, Urschel S, Belohradsky BH, Liese J. Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response. PLoS ONE. 2011;6(3):e17271
28. Hendrikx LH, Schure RM, Oztürk K, et al. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. Vaccine. 2011;29(40):6874-6880
29. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA. 2014;111(2):787-792
30. Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol. 2014;21(2):119-125
31. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med. 2013;368(6):583-584
32. Kamiya H. Decision and cost effectiveness analysis: a second dose of Tdap. Talk presented at: Meeting of the Advisory Council on Immunization Practices; June 19, 2013; Atlanta, GA. Available at: www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun13.pdf. Accessed August 1, 2013
33. Miller BL, Kretsinger K, Euler GL, Lu PJ, Ahmed F. Barriers to early uptake of tetanus, diphtheria and acellular pertussis vaccine (Tdap) among adults-United States, 2005-2007. Vaccine. 2011;29(22):3850-3856
34. Advisory Committee on Immunization Practices. Pertussis vaccines: working group conclusions on a second dose of Tdap. Talk presented at: Meeting of the Advisory Committee on Immunization Practices; June 19, 2013; Atlanta, GA. Available at: www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun13.pdf. Accessed August 1, 2013
35. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62(7):131-135